TY  - JOUR
AU  - Trpković, Andreja
AU  - Resanović, Ivana
AU  - Stanimirović, Julijana
AU  - Radak, Đorđe J.
AU  - Mousa, Shaker A.
AU  - Cenić-Milošević, Desanka
AU  - Jevremovic, Danimir
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/635
AB  - Atherosclerosis is a life-long illness that begins with risk factors, which in turn contribute to the development of subclinical disease, followed by the establishment of overt cardiovascular disease (CVD). Thrombotic-occlusive complications of atherosclerosis are among the most widespread and costly health problems. Oxidized low-density lipoprotein (OxLDL) plays an important role in atherogenesis by promoting an inflammatory environment and lipid deposition in the arterial wall. As cardiovascular events occur in individuals without common risk factors, there is a need for additional tools that may help in CVD risk assessment and management. The use of biomarkers has improved diagnostic, therapeutic and prognostic outcome in cardiovascular medicine. This review elaborates on the value of circulating OxLDL as a biomarker of CVD. Three enzyme-linked immunosorbent assays (4E6, DLH3 and E06) using murine monoclonal antibodies for determination of OxLDL blood levels have been developed. However, none of these assays are currently approved for routine clinical practice. We identified studies investigating OxLDL in CVD (measured by 4E6, DLH3 or E06 assay) by searching the PubMed database. Circulating OxLDL was found to be associated with all stages of atherosclerosis, from early atherogenesis to hypertension, coronary and peripheral arterial disease, acute coronary syndromes and ischemic cerebral infarction. The results of studies investigating the usefulness of OxLDL for CVD prediction were also summarized. Furthermore, OxLDL was found to be associated with pathologic conditions linked to CVD, including diabetes mellitus, obesity and metabolic syndrome (MetS). In addition, we have addressed the mechanisms by which OxLDL promotes atherogenesis, and the effects of antiatherogenic treatments on circulating OxLDL. Finally, we highlight the evidence suggesting that lipoprotein (a) [ Lp(a)] is the preferential carrier of oxidized phospholipids (OxPL) in human plasma. A strong association between OxPLapoB level (representing the content of OxPL on apolipoprotein B-100 particles, measured by E06 assay) and Lp(a) has been determined.
T2  - Critical Reviews in Clinical Laboratory Sciences
T1  - Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases
VL  - 52
IS  - 2
SP  - 70
EP  - 85
DO  - 10.3109/10408363.2014.992063
ER  - 

@article{
author = "Trpković, Andreja and Resanović, Ivana and Stanimirović, Julijana and Radak, Đorđe J. and Mousa, Shaker A. and Cenić-Milošević, Desanka and Jevremovic, Danimir and Isenović, Esma R.",
year = "2015",
abstract = "Atherosclerosis is a life-long illness that begins with risk factors, which in turn contribute to the development of subclinical disease, followed by the establishment of overt cardiovascular disease (CVD). Thrombotic-occlusive complications of atherosclerosis are among the most widespread and costly health problems. Oxidized low-density lipoprotein (OxLDL) plays an important role in atherogenesis by promoting an inflammatory environment and lipid deposition in the arterial wall. As cardiovascular events occur in individuals without common risk factors, there is a need for additional tools that may help in CVD risk assessment and management. The use of biomarkers has improved diagnostic, therapeutic and prognostic outcome in cardiovascular medicine. This review elaborates on the value of circulating OxLDL as a biomarker of CVD. Three enzyme-linked immunosorbent assays (4E6, DLH3 and E06) using murine monoclonal antibodies for determination of OxLDL blood levels have been developed. However, none of these assays are currently approved for routine clinical practice. We identified studies investigating OxLDL in CVD (measured by 4E6, DLH3 or E06 assay) by searching the PubMed database. Circulating OxLDL was found to be associated with all stages of atherosclerosis, from early atherogenesis to hypertension, coronary and peripheral arterial disease, acute coronary syndromes and ischemic cerebral infarction. The results of studies investigating the usefulness of OxLDL for CVD prediction were also summarized. Furthermore, OxLDL was found to be associated with pathologic conditions linked to CVD, including diabetes mellitus, obesity and metabolic syndrome (MetS). In addition, we have addressed the mechanisms by which OxLDL promotes atherogenesis, and the effects of antiatherogenic treatments on circulating OxLDL. Finally, we highlight the evidence suggesting that lipoprotein (a) [ Lp(a)] is the preferential carrier of oxidized phospholipids (OxPL) in human plasma. A strong association between OxPLapoB level (representing the content of OxPL on apolipoprotein B-100 particles, measured by E06 assay) and Lp(a) has been determined.",
journal = "Critical Reviews in Clinical Laboratory Sciences",
title = "Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases",
volume = "52",
number = "2",
pages = "70-85",
doi = "10.3109/10408363.2014.992063"
}

Trpković, A., Resanović, I., Stanimirović, J., Radak, Đ. J., Mousa, S. A., Cenić-Milošević, D., Jevremovic, D.,& Isenović, E. R.. (2015). Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. in Critical Reviews in Clinical Laboratory Sciences, 52(2), 70-85.
https://doi.org/10.3109/10408363.2014.992063

Trpković A, Resanović I, Stanimirović J, Radak ĐJ, Mousa SA, Cenić-Milošević D, Jevremovic D, Isenović ER. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. in Critical Reviews in Clinical Laboratory Sciences. 2015;52(2):70-85.
doi:10.3109/10408363.2014.992063 .

Trpković, Andreja, Resanović, Ivana, Stanimirović, Julijana, Radak, Đorđe J., Mousa, Shaker A., Cenić-Milošević, Desanka, Jevremovic, Danimir, Isenović, Esma R., "Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases" in Critical Reviews in Clinical Laboratory Sciences, 52, no. 2 (2015):70-85,
https://doi.org/10.3109/10408363.2014.992063 . .

TY  - JOUR
AU  - Antonijević, Đorđe
AU  - Jesthke, Anke
AU  - Čolović, Božana M.
AU  - Milovanović, Petar
AU  - Jevremovic, Danimir
AU  - Kisić, Danilo
AU  - vom Scheidt, Annika
AU  - Hahn, Michael
AU  - Amling, Michael
AU  - Jokanović, Vukoman R.
AU  - Busse, Bjoern
AU  - Đurić, Marija
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/847
AB  - Introduction: Calcium silicate cements (CSCs) with the addition of nanohydroxyapatite and calcium carbonate play a critical role in dental applications. To further improve their properties, particularly radiopacity and biointeractivity, the fluoride-containing radiopacifier ytterbium trifluoride (YbF3) was added to their composition, and biological and mechanical characteristics were evaluated. Methods: YbF3 was added to 3 different CSCs: cement I (CSC + calcium carbonate), cement II (CSC + nanohydroxyapatite), and Portland cement. Material characterization encompassed measurements of pH, calcium, ytterbium, and fluoride ion release; radiopacity; setting time; porosity; microindentation properties; wettability; and Fourier transform infrared spectroscopic, x-ray diffraction, and scanning electron microscopic analyses. Osteoblast- and osteoclast-like cells were grown on the materials surface to evaluate their adherence. Results: The addition of calcium carbonate, nanohydroxyapatite, and 30 wt% of YbF3 improved radiopacity and the setting time of experimental cements. The pH values did not differ among the groups. The greatest ytterbium and fluoride releases occurred in the Portland cement + YbF3 group. Combined x-ray diffraction and Fourier transform infrared spectroscopic analysis showed the presence of calcium hydroxide and calcium silicate hydrates. In addition, the presence of calcium ytterbium fluoride and ytterbium oxide proved that YbF3 reacted with cement compounds. Wettability of cement I + YbF3 was superior to other formulations, but its porosity and microindentation properties were weaker than in the Portland cement + YbF3 mixture. Cement II + YbF3 presented micromechanical indentation and porosity characteristics similar to the Portland-based cement formulation. Osteoclast- and osteoblast-like cells adhered to the cements surfaces without alteration of the cell structural integrity. Conclusions: YbF3-containing CSCs with nanostructured hydroxyapatite and calcium carbonate are well suited for dental application.
T2  - Journal of Endodontics
T1  - Addition of a Fluoride-containing Radiopacifier Improves Micromechanical and Biological Characteristics of Modified Calcium Silicate Cements
VL  - 41
IS  - 12
SP  - 2050
EP  - 2057
DO  - 10.1016/j.joen.2015.09.008
ER  - 

@article{
author = "Antonijević, Đorđe and Jesthke, Anke and Čolović, Božana M. and Milovanović, Petar and Jevremovic, Danimir and Kisić, Danilo and vom Scheidt, Annika and Hahn, Michael and Amling, Michael and Jokanović, Vukoman R. and Busse, Bjoern and Đurić, Marija",
year = "2015",
abstract = "Introduction: Calcium silicate cements (CSCs) with the addition of nanohydroxyapatite and calcium carbonate play a critical role in dental applications. To further improve their properties, particularly radiopacity and biointeractivity, the fluoride-containing radiopacifier ytterbium trifluoride (YbF3) was added to their composition, and biological and mechanical characteristics were evaluated. Methods: YbF3 was added to 3 different CSCs: cement I (CSC + calcium carbonate), cement II (CSC + nanohydroxyapatite), and Portland cement. Material characterization encompassed measurements of pH, calcium, ytterbium, and fluoride ion release; radiopacity; setting time; porosity; microindentation properties; wettability; and Fourier transform infrared spectroscopic, x-ray diffraction, and scanning electron microscopic analyses. Osteoblast- and osteoclast-like cells were grown on the materials surface to evaluate their adherence. Results: The addition of calcium carbonate, nanohydroxyapatite, and 30 wt% of YbF3 improved radiopacity and the setting time of experimental cements. The pH values did not differ among the groups. The greatest ytterbium and fluoride releases occurred in the Portland cement + YbF3 group. Combined x-ray diffraction and Fourier transform infrared spectroscopic analysis showed the presence of calcium hydroxide and calcium silicate hydrates. In addition, the presence of calcium ytterbium fluoride and ytterbium oxide proved that YbF3 reacted with cement compounds. Wettability of cement I + YbF3 was superior to other formulations, but its porosity and microindentation properties were weaker than in the Portland cement + YbF3 mixture. Cement II + YbF3 presented micromechanical indentation and porosity characteristics similar to the Portland-based cement formulation. Osteoclast- and osteoblast-like cells adhered to the cements surfaces without alteration of the cell structural integrity. Conclusions: YbF3-containing CSCs with nanostructured hydroxyapatite and calcium carbonate are well suited for dental application.",
journal = "Journal of Endodontics",
title = "Addition of a Fluoride-containing Radiopacifier Improves Micromechanical and Biological Characteristics of Modified Calcium Silicate Cements",
volume = "41",
number = "12",
pages = "2050-2057",
doi = "10.1016/j.joen.2015.09.008"
}

Antonijević, Đ., Jesthke, A., Čolović, B. M., Milovanović, P., Jevremovic, D., Kisić, D., vom Scheidt, A., Hahn, M., Amling, M., Jokanović, V. R., Busse, B.,& Đurić, M.. (2015). Addition of a Fluoride-containing Radiopacifier Improves Micromechanical and Biological Characteristics of Modified Calcium Silicate Cements. in Journal of Endodontics, 41(12), 2050-2057.
https://doi.org/10.1016/j.joen.2015.09.008

Antonijević Đ, Jesthke A, Čolović BM, Milovanović P, Jevremovic D, Kisić D, vom Scheidt A, Hahn M, Amling M, Jokanović VR, Busse B, Đurić M. Addition of a Fluoride-containing Radiopacifier Improves Micromechanical and Biological Characteristics of Modified Calcium Silicate Cements. in Journal of Endodontics. 2015;41(12):2050-2057.
doi:10.1016/j.joen.2015.09.008 .

Antonijević, Đorđe, Jesthke, Anke, Čolović, Božana M., Milovanović, Petar, Jevremovic, Danimir, Kisić, Danilo, vom Scheidt, Annika, Hahn, Michael, Amling, Michael, Jokanović, Vukoman R., Busse, Bjoern, Đurić, Marija, "Addition of a Fluoride-containing Radiopacifier Improves Micromechanical and Biological Characteristics of Modified Calcium Silicate Cements" in Journal of Endodontics, 41, no. 12 (2015):2050-2057,
https://doi.org/10.1016/j.joen.2015.09.008 . .

TY  - JOUR
AU  - Trpković, Andreja
AU  - Stanimirović, Julijana
AU  - Rizzo, Manfredi
AU  - Resanović, Ivana
AU  - Soskić, Sanja S.
AU  - Jevremovic, Danimir
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/613
AB  - The assessment of cardiovascular risk and treatment of cardiovascular diseases are major public health issues worldwide. Inflammation is now recognized as a key regulatory process that links multiple risk factors for atherosclerosis. The substantial number of patients having cardiovascular events lack commonly established risk factors. The utility of high-sensitivity C-reactive protein (hsCRP), a circulating biomarker related to inflammation, may provide additional information in risk prediction. This review will consider the impact of hsCRP level on initiation of statin therapy.
T2  - Angiology
T1  - High-Sensitivity C-Reactive Protein and Statin Initiation
VL  - 66
IS  - 6
SP  - 503
EP  - 507
DO  - 10.1177/0003319714543000
ER  - 

@article{
author = "Trpković, Andreja and Stanimirović, Julijana and Rizzo, Manfredi and Resanović, Ivana and Soskić, Sanja S. and Jevremovic, Danimir and Isenović, Esma R.",
year = "2015",
abstract = "The assessment of cardiovascular risk and treatment of cardiovascular diseases are major public health issues worldwide. Inflammation is now recognized as a key regulatory process that links multiple risk factors for atherosclerosis. The substantial number of patients having cardiovascular events lack commonly established risk factors. The utility of high-sensitivity C-reactive protein (hsCRP), a circulating biomarker related to inflammation, may provide additional information in risk prediction. This review will consider the impact of hsCRP level on initiation of statin therapy.",
journal = "Angiology",
title = "High-Sensitivity C-Reactive Protein and Statin Initiation",
volume = "66",
number = "6",
pages = "503-507",
doi = "10.1177/0003319714543000"
}

Trpković, A., Stanimirović, J., Rizzo, M., Resanović, I., Soskić, S. S., Jevremovic, D.,& Isenović, E. R.. (2015). High-Sensitivity C-Reactive Protein and Statin Initiation. in Angiology, 66(6), 503-507.
https://doi.org/10.1177/0003319714543000

Trpković A, Stanimirović J, Rizzo M, Resanović I, Soskić SS, Jevremovic D, Isenović ER. High-Sensitivity C-Reactive Protein and Statin Initiation. in Angiology. 2015;66(6):503-507.
doi:10.1177/0003319714543000 .

Trpković, Andreja, Stanimirović, Julijana, Rizzo, Manfredi, Resanović, Ivana, Soskić, Sanja S., Jevremovic, Danimir, Isenović, Esma R., "High-Sensitivity C-Reactive Protein and Statin Initiation" in Angiology, 66, no. 6 (2015):503-507,
https://doi.org/10.1177/0003319714543000 . .

TY  - JOUR
AU  - Trpković, Andreja
AU  - Stanimirović, Julijana
AU  - Resanović, Ivana
AU  - Otasevic, Petar
AU  - Jevremovic, Danimir
AU  - Radak, Đorđe J.
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/312
AB  - It is now recognized that inflammatory processes regulate all stages of atherosclerosis, from disease initiation to thrombotic complications. C-reactive protein (CRP) is a plasmatic protein used as a general marker of inflammation. The high sensitivity C-reactive protein (hsCRP) refers to the measurement of CRP in blood samples using assays with sufficient sensitivity to quantify low (baseline) levels of this biomarker. Low-grade chronic inflammatory processes are linked to atherosclerosis and may be screened with the use of hsCRP, thus providing additional information in cardiovascular risk prediction. This review elaborates the role of CRP in atherogenesis and the value of hsCRP as a biomarker in cardiovascular risk prediction in both primary and secondary prevention setting.
T2  - Current Pharmaceutical Analysis
T1  - High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction
VL  - 11
IS  - 1
SP  - 60
EP  - 65
DO  - 10.2174/1573412910666140822003911
ER  - 

@article{
author = "Trpković, Andreja and Stanimirović, Julijana and Resanović, Ivana and Otasevic, Petar and Jevremovic, Danimir and Radak, Đorđe J. and Isenović, Esma R.",
year = "2015",
abstract = "It is now recognized that inflammatory processes regulate all stages of atherosclerosis, from disease initiation to thrombotic complications. C-reactive protein (CRP) is a plasmatic protein used as a general marker of inflammation. The high sensitivity C-reactive protein (hsCRP) refers to the measurement of CRP in blood samples using assays with sufficient sensitivity to quantify low (baseline) levels of this biomarker. Low-grade chronic inflammatory processes are linked to atherosclerosis and may be screened with the use of hsCRP, thus providing additional information in cardiovascular risk prediction. This review elaborates the role of CRP in atherogenesis and the value of hsCRP as a biomarker in cardiovascular risk prediction in both primary and secondary prevention setting.",
journal = "Current Pharmaceutical Analysis",
title = "High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction",
volume = "11",
number = "1",
pages = "60-65",
doi = "10.2174/1573412910666140822003911"
}

Trpković, A., Stanimirović, J., Resanović, I., Otasevic, P., Jevremovic, D., Radak, Đ. J.,& Isenović, E. R.. (2015). High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction. in Current Pharmaceutical Analysis, 11(1), 60-65.
https://doi.org/10.2174/1573412910666140822003911

Trpković A, Stanimirović J, Resanović I, Otasevic P, Jevremovic D, Radak ĐJ, Isenović ER. High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction. in Current Pharmaceutical Analysis. 2015;11(1):60-65.
doi:10.2174/1573412910666140822003911 .

Trpković, Andreja, Stanimirović, Julijana, Resanović, Ivana, Otasevic, Petar, Jevremovic, Danimir, Radak, Đorđe J., Isenović, Esma R., "High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction" in Current Pharmaceutical Analysis, 11, no. 1 (2015):60-65,
https://doi.org/10.2174/1573412910666140822003911 . .

TY  - JOUR
AU  - Smiljanić, Katarina
AU  - Obradović, Milan M.
AU  - Jovanović, Aleksandra
AU  - Đorđević, Jelena D.
AU  - Dobutović, Branislava
AU  - Jevremovic, Danimir
AU  - Marche, Pierre
AU  - Isenović, Esma R.
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/134
AB  - In this study, the role of epidermal growth factor receptor (EGFR), extracellular signal-regulated kinase (ERK1/2), heparin-binding EGF-like growth factor (HB-EGF), general metalloproteinases, matrix metalloproteinases-2 (MMP-2) in mediating the mitogenic action of thrombin in rat vascular smooth muscle cells (VSMC) was investigated. The incubation of rat VSMC with thrombin (1 U/ml) for 5 min resulted in significant (p LT 0.001) increase of ERK1/2 phosphorylation by 8.7 +/- A 0.9-fold, EGFR phosphorylation by 8.5 +/- A 1.3-fold (p LT 0.001) and DNA synthesis by 3.6 +/- A 0.4-fold (p LT 0.001). Separate 30-min pretreatments with EGFR tyrosine kinase irreversible inhibitor, 10 A mu M PD169540 (PD), and 20 A mu M anti-HB-EGF antibody significantly reduced thrombin-stimulated EGFR and ERK1/2 phosphorylation by 81, 72 % and by 48 and 61 %, respectively. Furthermore, the same pretreatments with PD or anti-HB-EGF antibody reduced thrombin-induced VSMC proliferation by 44 and 45 %, respectively. In addition, 30-min pretreatments with 10 A mu M specific MMP-2 inhibitor significantly reduced thrombin-stimulated phosphorylation of both EGFR and ERK1/2 by 25 %. Moreover, the same pretreatment with MMP-2 inhibitor reduced thrombin-induced VSMC proliferation by 45 %. These results show that the thrombin-induced DNA synthesis correlates with the level of ERK1/2 activation rather than EGFR activation. These results further suggest that thrombin acts through EGFR and ERK 1/2 signaling pathways involving MMP-2 to upregulate proliferation of VSMC.
T2  - Molecular and Cellular Biochemistry
T1  - Thrombin stimulates VSMC proliferation through an EGFR-dependent pathway: involvement of MMP-2
VL  - 396
IS  - 1-2
SP  - 147
EP  - 160
DO  - 10.1007/s11010-014-2151-y
ER  - 

@article{
author = "Smiljanić, Katarina and Obradović, Milan M. and Jovanović, Aleksandra and Đorđević, Jelena D. and Dobutović, Branislava and Jevremovic, Danimir and Marche, Pierre and Isenović, Esma R.",
year = "2014",
abstract = "In this study, the role of epidermal growth factor receptor (EGFR), extracellular signal-regulated kinase (ERK1/2), heparin-binding EGF-like growth factor (HB-EGF), general metalloproteinases, matrix metalloproteinases-2 (MMP-2) in mediating the mitogenic action of thrombin in rat vascular smooth muscle cells (VSMC) was investigated. The incubation of rat VSMC with thrombin (1 U/ml) for 5 min resulted in significant (p LT 0.001) increase of ERK1/2 phosphorylation by 8.7 +/- A 0.9-fold, EGFR phosphorylation by 8.5 +/- A 1.3-fold (p LT 0.001) and DNA synthesis by 3.6 +/- A 0.4-fold (p LT 0.001). Separate 30-min pretreatments with EGFR tyrosine kinase irreversible inhibitor, 10 A mu M PD169540 (PD), and 20 A mu M anti-HB-EGF antibody significantly reduced thrombin-stimulated EGFR and ERK1/2 phosphorylation by 81, 72 % and by 48 and 61 %, respectively. Furthermore, the same pretreatments with PD or anti-HB-EGF antibody reduced thrombin-induced VSMC proliferation by 44 and 45 %, respectively. In addition, 30-min pretreatments with 10 A mu M specific MMP-2 inhibitor significantly reduced thrombin-stimulated phosphorylation of both EGFR and ERK1/2 by 25 %. Moreover, the same pretreatment with MMP-2 inhibitor reduced thrombin-induced VSMC proliferation by 45 %. These results show that the thrombin-induced DNA synthesis correlates with the level of ERK1/2 activation rather than EGFR activation. These results further suggest that thrombin acts through EGFR and ERK 1/2 signaling pathways involving MMP-2 to upregulate proliferation of VSMC.",
journal = "Molecular and Cellular Biochemistry",
title = "Thrombin stimulates VSMC proliferation through an EGFR-dependent pathway: involvement of MMP-2",
volume = "396",
number = "1-2",
pages = "147-160",
doi = "10.1007/s11010-014-2151-y"
}

Smiljanić, K., Obradović, M. M., Jovanović, A., Đorđević, J. D., Dobutović, B., Jevremovic, D., Marche, P.,& Isenović, E. R.. (2014). Thrombin stimulates VSMC proliferation through an EGFR-dependent pathway: involvement of MMP-2. in Molecular and Cellular Biochemistry, 396(1-2), 147-160.
https://doi.org/10.1007/s11010-014-2151-y

Smiljanić K, Obradović MM, Jovanović A, Đorđević JD, Dobutović B, Jevremovic D, Marche P, Isenović ER. Thrombin stimulates VSMC proliferation through an EGFR-dependent pathway: involvement of MMP-2. in Molecular and Cellular Biochemistry. 2014;396(1-2):147-160.
doi:10.1007/s11010-014-2151-y .

Smiljanić, Katarina, Obradović, Milan M., Jovanović, Aleksandra, Đorđević, Jelena D., Dobutović, Branislava, Jevremovic, Danimir, Marche, Pierre, Isenović, Esma R., "Thrombin stimulates VSMC proliferation through an EGFR-dependent pathway: involvement of MMP-2" in Molecular and Cellular Biochemistry, 396, no. 1-2 (2014):147-160,
https://doi.org/10.1007/s11010-014-2151-y . .